Fed. Circ. Mulls Generics' Invalidity Argument In Teva IP Row
A Federal Circuit judge wrestled Tuesday with arguments from Apotex and Mylan that a district court wrongly determined that their planned generic versions of Teva's cancer drug Bendeka infringed several patents...To view the full article, register now.
Already a subscriber? Click here to view full article